國家衛生研究院 NHRI:Item 3990099045/7153
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 858832      Online Users : 811
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7153


    Title: TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma
    Authors: Lan, J;Li, CF;Chen, TJ;Tai, HC;Huang, HY
    Contributors: National Institute of Cancer Research
    Abstract: Background: Despite the advances in diagnostic imaging and treatment modalities, the risk stratification and final outcomes in patients with nasopharyngeal carcinomas (NPC) still remain suboptimal. Through data mining from published transcriptomic database, TOP2A was first identified as a differentially upregulated gene in NPC tissues, which encodes topoisomerase 2 alpha implicating cell division via selective cleavage, rearrangement, and re-ligation of DNA strands. Given the roles of TOP2A in prognostication and as the frontline therapeutic target in common carcinomas, such as breast cancer, we explored the significance of TOP2A immunoexpression status in a well-defined cohort of NPC patients. Design: TOP2A immunohistochemistry was retrospectively performed and analyzed using H-score method for biopsy specimens from 124 NPC patients who received standard treatment without distant metastasis at initial diagnosis. Those cases with H-score larger than the median value were construed as featuring TOP2A overexpression. The results were correlated with the clinicopathological variables, disease-specific survival (DSS), and distant metastasis-free survival (DMFS). Results: TOP2A overexpression was significantly associated with AJCC stages III-IV (p=0.019) and univariately predictive of adverse outcomes for DSS (p=0.0078) and DMFS (p=0.0003). In multivariate comparisons, TOP2A overexpression still remained prognostically independent to portend worse DSS (p=0.047, hazard ratio=1.732) and DMFS (p=0.003, hazard ratio=2.569), together with advanced AJCC stages III-IV. Conclusions: TOP2A expression is upregulated in a subset of NPCs and its increased immunoexpression significantly correlated with advanced stages and tumor aggressiveness, justifying the potentiality of TOP2A as a prognostic biomarker and a novel therapeutic target of NPC.
    Date: 2013-02
    Relation: Laboratory Investigation. 2013 Feb;93(Suppl. 1):308A.
    Link to: http://dx.doi.org/10.1038/labinvest.2013.23
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0023-6837&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000314789301613
    Appears in Collections:[Others] Conference Papers/Meeting Abstract

    Files in This Item:

    File Description SizeFormat
    ISI000314789301613.pdf12032KbAdobe PDF417View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback